Premium
The Role of Natriuretic Peptides as Biomarkers for Guiding the Management of Chronic Heart Failure
Author(s) -
Motiwala S R,
Januzzi J L
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.187
Subject(s) - heart failure , biomarker , medicine , intensive care medicine , disease , population , biomarker discovery , natriuretic peptide , bioinformatics , proteomics , biology , biochemistry , environmental health , gene
The current standard treatment of chronic heart failure (HF) is based on clinical judgment, with the goal of achieving the maximally tolerated therapeutic program. The complexity of this approach may contribute to the well‐established treatment gaps that exist in HF management; consequently, the risks for morbidity and mortality in this population remain extremely high. Alternative means are needed to improve the outcomes of patients with HF. Natriuretic peptides are biological markers for HF disease—its presence, severity, and prognosis—and show unique interactions with therapeutics known to have benefit in HF. Accordingly, interest has recently developed in “biomarker‐guided” care for HF. This approach involves applying these assays to identify patients in need of therapy intensification and to provide an objective “monitor” of disease status. This review examines the biology of natriuretic peptides, discusses the rationale for their use in HF, and details the aggregate experience gained thus far in biomarker‐guided care. Clinical Pharmacology & Therapeutics (2013); 93 1, 57–67. doi: 10.1038/clpt.2012.187